Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse (Q79362747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Weltermann A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Fonatsch C

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Haas OA

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Greinix HT

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Kahls P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Mitterbauer G

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Jäger U

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Kainz B

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Geissler K

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sperr WR

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Knöbl P

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Schwarzinger I

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Gleiss A

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Lechner K

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 February 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

293-302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14671635%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403243

21 December 2019

exact match

0 references

cites work

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

The clinical significance of karyotype in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Prognostic factors in adult patients with acute leukemia at first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

The characteristics and outcome of patients with late relapse acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Prognosis of patients with a second relapse of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403243

7 January 2021